55 Presentations from Top Biopharma at PEGS Europe 2019
Developability Assessment to Select Candidates for Clinical Development
Anup Arumughan, PhD, Principal Scientist, Antibody Analytics, Roche
Preclinical Combinations of T Cell Bispecifics Targeting Solid Tumors and Hematological Malignancies
Marina Bacac, PhD, Head, Cancer Immunotherapy Department 2 (CIT-2), Roche Innovation Center Zurich
New Design of a Blast Freezer Thawer to Minimize Freeze-Thaw Associated Protein Aggregation
Karoline Bechtold-Peters, PhD, Senior Strategy and Technology Leader, Biologics Technical Development & Manufacturing, Novartis Pharma AG
A Development and Manufacturing Platform for Non-Platform Proteins
Matthias Berkemeyer, PhD, Associate Director, Downstream Development, NBE and Biosimilars, Biopharma Process Science Austria, Boehringer Ingelheim RCV GmbH & Co KG
Bispecific Target Discovery by High-Throughput Functional Screening
Pallavi Bhatta, PhD, Principal Scientist, Bispecific Target Discovery, UCB
Discovery of Potent Human Therapeutic Antibodies Using Phage and Yeast Display Technologies
Thomas Bouquin, PhD, Head, Biologics Research France, Centre de Recherche de Vitry/Alfortville, Sanofi
Targeted Antibody-Prodrugs
Ulrich Brinkmann, PhD, Expert Scientist, Large Molecule Research, Roche Pharma Research & Early Development, Roche
A Simple IgG-like Discovery Platform for a Complex IgG-like (1+1) Format
Régis Cebe, MSc, Scientific Technical Leader, Novartis Biologic Centre, Novartis Institute of Biomedical Research
Monitoring of Clearance of Lipase Host Cell Proteins in mAb Manufacturing Using a LC-MRM Quantitation Method
Rachel Chen, PhD, Scientist II, Analytical Development, Biogen
Combining Deep Sequencing and High Throughput B Cell Technologies to Maximize Functional Activity Guided Antibodies Discovery and Optimization
Gabriel WC Cheung, PhD, Senior Director, BioMedicine Design, Pfizer, Inc.
Multi-Specific Agent to Overcome Potential Resistance to Influenza
Mark Chiu, PhD, Associate Director, BioTherapeutics Analytical Development, Janssen Research & Development LLC
Overcoming Some Challenges in the Purification of Bispecific Antibodies
Ana Correia, PhD, Scientist, Biologics Optimization, Amgen, Inc.
A Novel Mucin 16 Bispecific T Cell Engaging Antibody for the Treatment of Ovarian Cancer
Alison Crawford, PhD, Senior Staff Scientist, Oncology and Angiogenesis, Regeneron Pharmaceuticals, Inc.
Targeted Thorium Conjugates (TTCs): A New Modality for the Treatment of Cancer Utilizing Alpha Particle-Based Radiotherapy
Alan Cuthbertson, PhD, Head of Thorium R&D, TCR, Bayer AS
An Integrated Approach for Optimization and Developability Assessment of Peptides Intended for Multiple-Dose Pen Devices
Andreas Evers, PhD, Senior Scientist, Synthetic Molecular Design, Integrated Drug Discovery, Sanofi
The Making of a Biparatopic Molecule
Fernando Garces, PhD, Senior Scientist, Biologics Optimization, Amgen, Inc.
The Contorsbody, a Format for Agonism: Design, Structure, Function
Guy Georges, PhD, Expert Scientist, Large Molecule Research, Roche Innovation Center Munich
Quantitation of HCP by Mass Spectrometry as a Method to Control the Quality of Biopharmaceuticals
Annick Gervais, PhD, Director, Analytical Development, Biologicals, UCB Pharma SA
Developing Bi- & Multi-Specific Immune-Modulatory Biologics to Address Unmet Needs
Tariq Ghayur, PhD, Distinguished Research Fellow, AbbVie Bioresearch Center
A New Platform for the Identification of Synergistic Bispecific Combinations
Elke Glasmacher, PhD, Head, Immunobiology, Large Molecule Research, pRED, Roche Innovation Center
Antibody Discovery for Metabolic Enzyme and Immuno-Oncology Targets
Maria Groves, PhD, Associate Director, Lab Head for the CRUK/Medimmune Alliance, AstraZeneca
Developability Assessment to Enable Candidate Selection of Therapeutic Proteins
Steffen Hartmann, PhD, Head, Characterization, Formulation and Bioinformatics, Novartis Pharma AG
Monitoring and Characterizing Aggregation Variants in Co-Formulated Biologic Products: Utilizing 2D Chromatography to Assess Aggregation
Mark Anthony Haverick, Associate Principal Scientist, Biologics Analytical R&D, MSD
Deep Sequencing of Natural Antibody Repertoires for Antibody Discovery and Optimization and Elucidation of Repertoire Properties
Isidro Hotzel, PhD, Senior Scientist, Antibody Engineering, Genentech, Inc.
Bispecific Antibodies: Discovery, Development, and Next Generation
Tomoyuki Igawa, PhD, CEO, Head, Research, Global Biologics Leader, Chugai Pharmabody Research Pte. Ltd
Optimization of Preclinical Safety and Efficacy of Anti-HER2/CD3
Teemu Junttila, PhD, Senior Scientist, Translational Oncology, Genentech, Inc.
Physicochemical Predictors of Antibody Solution Behavior
Jonathan Kingsbury, PhD, Head, Developability and Preformulation, Biologics Development, Sanofi
Targeting Cancer with BiTE® Antibody Constructs
Roman Kischel, MD, Director, Research, Amgen Research (Munich) GmbH
Tumor-Targeted 4-1BB Co-Stimulation to Boost T Cell Activity for Cancer Immunotherapy
Christian Klein, PhD, Head of Oncology Programs & Department Head of Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharmaceutical Research and Early Development
Humanization and Simultaneous Optimization of Monoclonal and Bispecific Antibody
Christine X. Koo, PhD, Senior Scientist 1, Lead Optimization, Chugai Pharmabody Research
Understanding Protein Aggregation via Computational Means
Sandeep Kumar, PhD, Senior Research Fellow, Biotherapeutics, Boehringer-Ingelheim Pharmaceuticals
Toward in silico Lead Discovery
Lars Linden, PhD, Director & Head, Protein Biochemistry, Bayer Healthcare AG
Aptamers and Enzyme Cascades as New Tools for Analytical Characterization of Biopharmaceuticals
Urs Lohrig, PhD, Lab Head, Physico-Chemical Characterisation, Novartis
Biophysical Screening of Unwanted Protein Interactions
Nikolai Lorenzen, PhD, Specialist, Biophysics and Formulation, Novo Nordisk A/S
Novel Protein A Small and Large-Scale Purification Platforms for Bispecific Antibodies
Afshin Mahmoudi, MS, Biotherapeutics, Signal Pharmaceuticals, LLC (a wholly owned subsidiary of Celgene Corp.)
Solution NMR Assessments of Therapeutic Protein Behavior
Mark McCoy, PhD, Principal Scientist, Discovery Chemistry – Screening, Target and Compound Profiling, MSD
Characterization from Developability to BLA
Jean-Michel Menet, PhD, Head, Characterization, Biologics Development/BioAnalytics, Sanofi
A Reliable and Automated Workflow for LC-MS MAM Analysis of Biopharmaceuticals – From High Throughput Sample Preparation to Data Evaluation
Patrick Sascha Merkle, PhD, Postdoc, Analytical Development & Characterization, Novartis Pharma AG
Advancing Therapeutic Protein Development Using a Novel O-Glycan-Based Conjugation Approach
Monika Papworth, PhD, Senior Scientist, Antibody Discovery and Protein Engineering, AstraZeneca
Precise Genome Engineering of Hybridomas for Antibody Expression and Screening
Cristina Parola, PhD, Postdoctoral Research Scientist, Biologics Research, Sanofi
Development of a Pre-Glycoengineered CHO-K1 Host Cell Line for the Expression of Antibodies with Enhanced Fc Mediated Effector Function
Oliver Popp, Dr. rer. nat., Principle Scientist, pRED, Large Molecule Research, Roche Diagnostics GmbH, Roche Innovation Center Munich
Characterization of Subvisible Particles: Old Challenges and Newest Improvements
Anacelia Rios Quiroz, PhD, Scientist, Group Leader, Particle Lab, Pharma Technical Development Biologics Europe, Hoffmann-La Roche
Discovery and Optimization of a Novel T Cell Bispecific for the Treatment of Solid Tumors
Adam Root, MSc, Senior Principal Scientist, BioMedicine Design, Pfizer Inc.
Effective Management of ADC Development and Clinical Manufacturing Including Outsourcing – A Big Pharma Perspective
Ulrich Rümenapp, PhD, Head, Launch Preparation and Coordination, Bayer AG
Bioconjugates: Development of an Efficient and Scalable Maleimide Linker Stabilization Method
Pegah Saremirad, PhD, Scientist, Process Development, AstraZeneca
Expanding the CHO CLD Toolbox to Enable Fast-Track Development of Innovative Biotherapeutics
Valerie Schmieder, PhD, Postdoctoral Researcher, BioProcess & Analytical Development Department, Boehringer Ingelheim Pharma GmbH & Co. KG
Begin with Quality in Mind: Identifying CQAs from Early Stage of Product Lifecycle
Archana Shah, PhD, Investigator, GlaxoSmithKline
Bintrafusp Alfa (M7824): A New Class of Next Generation Immune-Oncology Agent Targeting PDL-1 and TGF-Beta
Michael R. Streit, PhD, Executive Director, Cancer Epigenetics, GlaxoSmithKline
Strategy to Establish Clinically Relevant Specifications at Launch
John Stults, PhD, Director, Protein Analytical Chemistry, Genentech, Inc.
Novel Antibody Engineering to Improve Therapeutic Index of Antibody Targeting Solid Tumors
Kanako Tatsumi, PhD, Researcher, Discovery Biologics, Chugai Pharmaceutical Co. Ltd.
Chemometrics and Advanced Data Analytics for Particle Analysis
Jonas Hoeg Thygesen, PhD, Area Specialist, R&D Microanalysis, Novo Nordisk Pharmatech A/S
Study of the Impact of Proximal Chromosomal Environment Alterations Using a Targeted Integration CHO Host Cell Line
Mark Trautwein, Dr. rer. nat., Senior Scientist, Biologics Research, Bayer AG
Strategies to Isolate and Engineer Functional Antibodies against GPCR and Ion Channel Targets
Trevor Wilkinson, PhD, Associate Director, Antibody Discovery and Protein Engineering, AstraZeneca
GSK3359609- Anti-ICOS IgG4 Antibody Engineered for Optimized T Cell Agonist Effects Translating to Anti-Tumor Responses in the Clinic
Sapna Yadavilli, PhD, Associate Fellow, Precision Medicine Lead, Clinical Biomarkers and Experimental Medicine, Oncology TA, GlaxoSmithKline
Targeting Tumor-Associated Macrophages to Improve Cancer Immunotherapy
Minhong Yan, PhD, Principal Scientist, Molecular Oncology, Genentech, Inc.
Novel Strategies for the Generation of Yeast Surface Display and Phage Display Antibody Libraries
Stefan Zielonka, PhD, Associate Director, Protein Engineering & Antibody Technologies, Discovery Technologies, Global Research and Development, Merck Healthcare KGaA